Click Therapeutics Stock
Digital Therapeutics Applications
Sign up today and learn more about Click Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Click Therapeutics Stock
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.
Investors
Flatiron Investors
Magellan Health Services
K2 HealthVentures
Sanofi
Hikma Ventures
Funding History
June 2018 | $33.1M |
---|---|
October 2021 | $57.8M |
Management
Chief Executive Officer
David Benshoof Klein
Chief Technology Officer
Christopher Jordan
Press
businesswire - Feb, 19 2024
Click Therapeutics Secures $20 Million Debt Financing from HSBCmedcitynews - Dec, 19 2023
Rigorous Data Are Key to Convince Payers, Investors in the ...mhealthintelligence - Dec, 19 2023
In a Maturing Digital Health Market, Players Must Adapt Their ...finance - Dec, 19 2023
Click Therapeutics Secures $20 Million Debt Financing from ...businesswire - Nov, 9 2023
Click Therapeutics Announces Participation in November Investor Conferences